EHMT2 and acute myeloid leukemia: He et al. (2019) have also clarified that EZH2 is associated with drug resistance and deterioration of MDS, as well as the progression from MDS to AML. Lehnertz et al. (2014) have shown that EHMT2 inhibitor can significantly delay the progression of disease and reduce the frequency of leukemia stem cells in a mouse model of AML.